Global Attenuated Vaccine for Human Rabies Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
The global market for Attenuated Vaccine for Human Rabies is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Attenuated Vaccine for Human Rabies players cover AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc and Cadila Pharmaceuticals Ltd, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Attenuated Vaccine for Human Rabies market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Attenuated Vaccine for Human Rabies market, with both quantitative and qualitative data, to help readers understand how the Attenuated Vaccine for Human Rabies market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Attenuated Vaccine for Human Rabies market and forecasts the market size by Type (Vero Cell and Human Diploid Cell,), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of Attenuated Vaccine for Human Rabies, Research Methodology, etc.
Chapter 2: Executive Summary, global Attenuated Vaccine for Human Rabies market size (sales and revenue) and CAGR, Attenuated Vaccine for Human Rabies market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Attenuated Vaccine for Human Rabies sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Attenuated Vaccine for Human Rabies sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Attenuated Vaccine for Human Rabies market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, Cadila Pharmaceuticals Ltd, Novartis AG, Pfizer Inc, Liaoning Yisheng Biopharmaceutical Co., Ltd and Lanzhou Institute of Biological Products Co., Ltd, etc.
Chapter 14: Research Findings and Conclusion
The global market for Attenuated Vaccine for Human Rabies is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Attenuated Vaccine for Human Rabies market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Attenuated Vaccine for Human Rabies players cover AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc and Cadila Pharmaceuticals Ltd, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Attenuated Vaccine for Human Rabies market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Attenuated Vaccine for Human Rabies market, with both quantitative and qualitative data, to help readers understand how the Attenuated Vaccine for Human Rabies market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Attenuated Vaccine for Human Rabies market and forecasts the market size by Type (Vero Cell and Human Diploid Cell,), by Application (Hospital and Clinic.), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Vero Cell
- Human Diploid Cell
- Hospital
- Clinic
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- GlaxoSmithKline
- Merck & Co Inc
- Sanofi Pasteur, Inc
- Cadila Pharmaceuticals Ltd
- Novartis AG
- Pfizer Inc
- Liaoning Yisheng Biopharmaceutical Co., Ltd
- Lanzhou Institute of Biological Products Co., Ltd
- Changchun Zhuoyi Biological Co., Ltd
- Guangzhou Nuocheng Biological Products Co., Ltd
- Ningbo Rongan Biopharmaceutical Co., Ltd
- Shandong Yidu Biotechnology Co., Ltd
- Chengdu Kanghua Biological Products Co., Ltd
- Wuhan Institute of Biological Products Co., Ltd
Chapter 1: Scope of Attenuated Vaccine for Human Rabies, Research Methodology, etc.
Chapter 2: Executive Summary, global Attenuated Vaccine for Human Rabies market size (sales and revenue) and CAGR, Attenuated Vaccine for Human Rabies market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Attenuated Vaccine for Human Rabies sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Attenuated Vaccine for Human Rabies sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Attenuated Vaccine for Human Rabies market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, Cadila Pharmaceuticals Ltd, Novartis AG, Pfizer Inc, Liaoning Yisheng Biopharmaceutical Co., Ltd and Lanzhou Institute of Biological Products Co., Ltd, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Attenuated Vaccine for Human Rabies by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Attenuated Vaccine for Human Rabies by Country/Region, 2017, 2022 & 2028
2.2 Attenuated Vaccine for Human Rabies Segment by Type
2.2.1 Vero Cell
2.2.2 Human Diploid Cell
2.3 Attenuated Vaccine for Human Rabies Sales by Type
2.3.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
2.3.2 Global Attenuated Vaccine for Human Rabies Revenue and Market Share by Type (2017-2022)
2.3.3 Global Attenuated Vaccine for Human Rabies Sale Price by Type (2017-2022)
2.4 Attenuated Vaccine for Human Rabies Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Attenuated Vaccine for Human Rabies Sales by Application
2.5.1 Global Attenuated Vaccine for Human Rabies Sale Market Share by Application (2017-2022)
2.5.2 Global Attenuated Vaccine for Human Rabies Revenue and Market Share by Application (2017-2022)
2.5.3 Global Attenuated Vaccine for Human Rabies Sale Price by Application (2017-2022)
3 GLOBAL ATTENUATED VACCINE FOR HUMAN RABIES BY COMPANY
3.1 Global Attenuated Vaccine for Human Rabies Breakdown Data by Company
3.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Company (2020-2022)
3.1.2 Global Attenuated Vaccine for Human Rabies Sales Market Share by Company (2020-2022)
3.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Company (2020-2022)
3.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Company (2020-2022)
3.2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company (2020-2022)
3.3 Global Attenuated Vaccine for Human Rabies Sale Price by Company
3.4 Key Manufacturers Attenuated Vaccine for Human Rabies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Attenuated Vaccine for Human Rabies Product Location Distribution
3.4.2 Players Attenuated Vaccine for Human Rabies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ATTENUATED VACCINE FOR HUMAN RABIES BY GEOGRAPHIC REGION
4.1 World Historic Attenuated Vaccine for Human Rabies Market Size by Geographic Region (2017-2022)
4.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Geographic Region
4.2 World Historic Attenuated Vaccine for Human Rabies Market Size by Country/Region (2017-2022)
4.2.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Country/Region (2017-2022)
4.2.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Country/Region
4.3 Americas Attenuated Vaccine for Human Rabies Sales Growth
4.4 APAC Attenuated Vaccine for Human Rabies Sales Growth
4.5 Europe Attenuated Vaccine for Human Rabies Sales Growth
4.6 Middle East & Africa Attenuated Vaccine for Human Rabies Sales Growth
5 AMERICAS
5.1 Americas Attenuated Vaccine for Human Rabies Sales by Country
5.1.1 Americas Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
5.1.2 Americas Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
5.2 Americas Attenuated Vaccine for Human Rabies Sales by Type
5.3 Americas Attenuated Vaccine for Human Rabies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Attenuated Vaccine for Human Rabies Sales by Region
6.1.1 APAC Attenuated Vaccine for Human Rabies Sales by Region (2017-2022)
6.1.2 APAC Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022)
6.2 APAC Attenuated Vaccine for Human Rabies Sales by Type
6.3 APAC Attenuated Vaccine for Human Rabies Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Attenuated Vaccine for Human Rabies by Country
7.1.1 Europe Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
7.1.2 Europe Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
7.2 Europe Attenuated Vaccine for Human Rabies Sales by Type
7.3 Europe Attenuated Vaccine for Human Rabies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Attenuated Vaccine for Human Rabies by Country
8.1.1 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
8.1.2 Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
8.2 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Type
8.3 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Attenuated Vaccine for Human Rabies
10.3 Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies
10.4 Industry Chain Structure of Attenuated Vaccine for Human Rabies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Attenuated Vaccine for Human Rabies Distributors
11.3 Attenuated Vaccine for Human Rabies Customer
12 WORLD FORECAST REVIEW FOR ATTENUATED VACCINE FOR HUMAN RABIES BY GEOGRAPHIC REGION
12.1 Global Attenuated Vaccine for Human Rabies Market Size Forecast by Region
12.1.1 Global Attenuated Vaccine for Human Rabies Forecast by Region (2023-2028)
12.1.2 Global Attenuated Vaccine for Human Rabies Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Attenuated Vaccine for Human Rabies Forecast by Type
12.7 Global Attenuated Vaccine for Human Rabies Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Attenuated Vaccine for Human Rabies Product Offered
13.1.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Offered
13.2.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Merck & Co Inc
13.3.1 Merck & Co Inc Company Information
13.3.2 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Offered
13.3.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Merck & Co Inc Main Business Overview
13.3.5 Merck & Co Inc Latest Developments
13.4 Sanofi Pasteur, Inc
13.4.1 Sanofi Pasteur, Inc Company Information
13.4.2 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Offered
13.4.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Pasteur, Inc Main Business Overview
13.4.5 Sanofi Pasteur, Inc Latest Developments
13.5 Cadila Pharmaceuticals Ltd
13.5.1 Cadila Pharmaceuticals Ltd Company Information
13.5.2 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Offered
13.5.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Cadila Pharmaceuticals Ltd Main Business Overview
13.5.5 Cadila Pharmaceuticals Ltd Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Attenuated Vaccine for Human Rabies Product Offered
13.6.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Pfizer Inc
13.7.1 Pfizer Inc Company Information
13.7.2 Pfizer Inc Attenuated Vaccine for Human Rabies Product Offered
13.7.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Pfizer Inc Main Business Overview
13.7.5 Pfizer Inc Latest Developments
13.8 Liaoning Yisheng Biopharmaceutical Co., Ltd
13.8.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
13.8.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.8.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Main Business Overview
13.8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Latest Developments
13.9 Lanzhou Institute of Biological Products Co., Ltd
13.9.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
13.9.2 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.9.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview
13.9.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments
13.10 Changchun Zhuoyi Biological Co., Ltd
13.10.1 Changchun Zhuoyi Biological Co., Ltd Company Information
13.10.2 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.10.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Changchun Zhuoyi Biological Co., Ltd Main Business Overview
13.10.5 Changchun Zhuoyi Biological Co., Ltd Latest Developments
13.11 Guangzhou Nuocheng Biological Products Co., Ltd
13.11.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
13.11.2 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.11.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Guangzhou Nuocheng Biological Products Co., Ltd Main Business Overview
13.11.5 Guangzhou Nuocheng Biological Products Co., Ltd Latest Developments
13.12 Ningbo Rongan Biopharmaceutical Co., Ltd
13.12.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
13.12.2 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.12.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Ningbo Rongan Biopharmaceutical Co., Ltd Main Business Overview
13.12.5 Ningbo Rongan Biopharmaceutical Co., Ltd Latest Developments
13.13 Shandong Yidu Biotechnology Co., Ltd
13.13.1 Shandong Yidu Biotechnology Co., Ltd Company Information
13.13.2 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.13.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Shandong Yidu Biotechnology Co., Ltd Main Business Overview
13.13.5 Shandong Yidu Biotechnology Co., Ltd Latest Developments
13.14 Chengdu Kanghua Biological Products Co., Ltd
13.14.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
13.14.2 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.14.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Chengdu Kanghua Biological Products Co., Ltd Main Business Overview
13.14.5 Chengdu Kanghua Biological Products Co., Ltd Latest Developments
13.15 Wuhan Institute of Biological Products Co., Ltd
13.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
13.15.2 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.15.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Wuhan Institute of Biological Products Co., Ltd Main Business Overview
13.15.5 Wuhan Institute of Biological Products Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Attenuated Vaccine for Human Rabies by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Attenuated Vaccine for Human Rabies by Country/Region, 2017, 2022 & 2028
2.2 Attenuated Vaccine for Human Rabies Segment by Type
2.2.1 Vero Cell
2.2.2 Human Diploid Cell
2.3 Attenuated Vaccine for Human Rabies Sales by Type
2.3.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
2.3.2 Global Attenuated Vaccine for Human Rabies Revenue and Market Share by Type (2017-2022)
2.3.3 Global Attenuated Vaccine for Human Rabies Sale Price by Type (2017-2022)
2.4 Attenuated Vaccine for Human Rabies Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Attenuated Vaccine for Human Rabies Sales by Application
2.5.1 Global Attenuated Vaccine for Human Rabies Sale Market Share by Application (2017-2022)
2.5.2 Global Attenuated Vaccine for Human Rabies Revenue and Market Share by Application (2017-2022)
2.5.3 Global Attenuated Vaccine for Human Rabies Sale Price by Application (2017-2022)
3 GLOBAL ATTENUATED VACCINE FOR HUMAN RABIES BY COMPANY
3.1 Global Attenuated Vaccine for Human Rabies Breakdown Data by Company
3.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Company (2020-2022)
3.1.2 Global Attenuated Vaccine for Human Rabies Sales Market Share by Company (2020-2022)
3.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Company (2020-2022)
3.2.1 Global Attenuated Vaccine for Human Rabies Revenue by Company (2020-2022)
3.2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company (2020-2022)
3.3 Global Attenuated Vaccine for Human Rabies Sale Price by Company
3.4 Key Manufacturers Attenuated Vaccine for Human Rabies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Attenuated Vaccine for Human Rabies Product Location Distribution
3.4.2 Players Attenuated Vaccine for Human Rabies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ATTENUATED VACCINE FOR HUMAN RABIES BY GEOGRAPHIC REGION
4.1 World Historic Attenuated Vaccine for Human Rabies Market Size by Geographic Region (2017-2022)
4.1.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Geographic Region
4.2 World Historic Attenuated Vaccine for Human Rabies Market Size by Country/Region (2017-2022)
4.2.1 Global Attenuated Vaccine for Human Rabies Annual Sales by Country/Region (2017-2022)
4.2.2 Global Attenuated Vaccine for Human Rabies Annual Revenue by Country/Region
4.3 Americas Attenuated Vaccine for Human Rabies Sales Growth
4.4 APAC Attenuated Vaccine for Human Rabies Sales Growth
4.5 Europe Attenuated Vaccine for Human Rabies Sales Growth
4.6 Middle East & Africa Attenuated Vaccine for Human Rabies Sales Growth
5 AMERICAS
5.1 Americas Attenuated Vaccine for Human Rabies Sales by Country
5.1.1 Americas Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
5.1.2 Americas Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
5.2 Americas Attenuated Vaccine for Human Rabies Sales by Type
5.3 Americas Attenuated Vaccine for Human Rabies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Attenuated Vaccine for Human Rabies Sales by Region
6.1.1 APAC Attenuated Vaccine for Human Rabies Sales by Region (2017-2022)
6.1.2 APAC Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022)
6.2 APAC Attenuated Vaccine for Human Rabies Sales by Type
6.3 APAC Attenuated Vaccine for Human Rabies Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Attenuated Vaccine for Human Rabies by Country
7.1.1 Europe Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
7.1.2 Europe Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
7.2 Europe Attenuated Vaccine for Human Rabies Sales by Type
7.3 Europe Attenuated Vaccine for Human Rabies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Attenuated Vaccine for Human Rabies by Country
8.1.1 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2017-2022)
8.1.2 Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022)
8.2 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Type
8.3 Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Attenuated Vaccine for Human Rabies
10.3 Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies
10.4 Industry Chain Structure of Attenuated Vaccine for Human Rabies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Attenuated Vaccine for Human Rabies Distributors
11.3 Attenuated Vaccine for Human Rabies Customer
12 WORLD FORECAST REVIEW FOR ATTENUATED VACCINE FOR HUMAN RABIES BY GEOGRAPHIC REGION
12.1 Global Attenuated Vaccine for Human Rabies Market Size Forecast by Region
12.1.1 Global Attenuated Vaccine for Human Rabies Forecast by Region (2023-2028)
12.1.2 Global Attenuated Vaccine for Human Rabies Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Attenuated Vaccine for Human Rabies Forecast by Type
12.7 Global Attenuated Vaccine for Human Rabies Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Attenuated Vaccine for Human Rabies Product Offered
13.1.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Offered
13.2.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Merck & Co Inc
13.3.1 Merck & Co Inc Company Information
13.3.2 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Offered
13.3.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Merck & Co Inc Main Business Overview
13.3.5 Merck & Co Inc Latest Developments
13.4 Sanofi Pasteur, Inc
13.4.1 Sanofi Pasteur, Inc Company Information
13.4.2 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Offered
13.4.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Pasteur, Inc Main Business Overview
13.4.5 Sanofi Pasteur, Inc Latest Developments
13.5 Cadila Pharmaceuticals Ltd
13.5.1 Cadila Pharmaceuticals Ltd Company Information
13.5.2 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Offered
13.5.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Cadila Pharmaceuticals Ltd Main Business Overview
13.5.5 Cadila Pharmaceuticals Ltd Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Attenuated Vaccine for Human Rabies Product Offered
13.6.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Pfizer Inc
13.7.1 Pfizer Inc Company Information
13.7.2 Pfizer Inc Attenuated Vaccine for Human Rabies Product Offered
13.7.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Pfizer Inc Main Business Overview
13.7.5 Pfizer Inc Latest Developments
13.8 Liaoning Yisheng Biopharmaceutical Co., Ltd
13.8.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
13.8.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.8.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Main Business Overview
13.8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Latest Developments
13.9 Lanzhou Institute of Biological Products Co., Ltd
13.9.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
13.9.2 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.9.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview
13.9.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments
13.10 Changchun Zhuoyi Biological Co., Ltd
13.10.1 Changchun Zhuoyi Biological Co., Ltd Company Information
13.10.2 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.10.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Changchun Zhuoyi Biological Co., Ltd Main Business Overview
13.10.5 Changchun Zhuoyi Biological Co., Ltd Latest Developments
13.11 Guangzhou Nuocheng Biological Products Co., Ltd
13.11.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
13.11.2 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.11.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Guangzhou Nuocheng Biological Products Co., Ltd Main Business Overview
13.11.5 Guangzhou Nuocheng Biological Products Co., Ltd Latest Developments
13.12 Ningbo Rongan Biopharmaceutical Co., Ltd
13.12.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
13.12.2 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.12.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Ningbo Rongan Biopharmaceutical Co., Ltd Main Business Overview
13.12.5 Ningbo Rongan Biopharmaceutical Co., Ltd Latest Developments
13.13 Shandong Yidu Biotechnology Co., Ltd
13.13.1 Shandong Yidu Biotechnology Co., Ltd Company Information
13.13.2 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.13.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Shandong Yidu Biotechnology Co., Ltd Main Business Overview
13.13.5 Shandong Yidu Biotechnology Co., Ltd Latest Developments
13.14 Chengdu Kanghua Biological Products Co., Ltd
13.14.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
13.14.2 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.14.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Chengdu Kanghua Biological Products Co., Ltd Main Business Overview
13.14.5 Chengdu Kanghua Biological Products Co., Ltd Latest Developments
13.15 Wuhan Institute of Biological Products Co., Ltd
13.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
13.15.2 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
13.15.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Wuhan Institute of Biological Products Co., Ltd Main Business Overview
13.15.5 Wuhan Institute of Biological Products Co., Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Attenuated Vaccine for Human Rabies Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Attenuated Vaccine for Human Rabies Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Vero Cell
Table 4. Major Players of Human Diploid Cell
Table 5. Global Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 6. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 7. Global Attenuated Vaccine for Human Rabies Revenue by Type (2017-2022) & ($ million)
Table 8. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2017-2022)
Table 9. Global Attenuated Vaccine for Human Rabies Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 11. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 12. Global Attenuated Vaccine for Human Rabies Revenue by Application (2017-2022)
Table 13. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2017-2022)
Table 14. Global Attenuated Vaccine for Human Rabies Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Attenuated Vaccine for Human Rabies Sales by Company (2020-2022) & (K Units)
Table 16. Global Attenuated Vaccine for Human Rabies Sales Market Share by Company (2020-2022)
Table 17. Global Attenuated Vaccine for Human Rabies Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company (2020-2022)
Table 19. Global Attenuated Vaccine for Human Rabies Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Attenuated Vaccine for Human Rabies Producing Area Distribution and Sales Area
Table 21. Players Attenuated Vaccine for Human Rabies Products Offered
Table 22. Attenuated Vaccine for Human Rabies Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Attenuated Vaccine for Human Rabies Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Attenuated Vaccine for Human Rabies Sales Market Share Geographic Region (2017-2022)
Table 27. Global Attenuated Vaccine for Human Rabies Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Attenuated Vaccine for Human Rabies Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Attenuated Vaccine for Human Rabies Sales Market Share by Country/Region (2017-2022)
Table 31. Global Attenuated Vaccine for Human Rabies Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 34. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 35. Americas Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 37. Americas Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 38. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 39. Americas Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 40. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 41. APAC Attenuated Vaccine for Human Rabies Sales by Region (2017-2022) & (K Units)
Table 42. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)
Table 43. APAC Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2017-2022)
Table 45. APAC Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 46. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 47. APAC Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 48. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 49. Europe Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 50. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 51. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 53. Europe Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 54. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 55. Europe Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 56. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Attenuated Vaccine for Human Rabies
Table 66. Key Market Challenges & Risks of Attenuated Vaccine for Human Rabies
Table 67. Key Industry Trends of Attenuated Vaccine for Human Rabies
Table 68. Attenuated Vaccine for Human Rabies Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Attenuated Vaccine for Human Rabies Distributors List
Table 71. Attenuated Vaccine for Human Rabies Customer List
Table 72. Global Attenuated Vaccine for Human Rabies Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Attenuated Vaccine for Human Rabies Sales Market Forecast by Region
Table 74. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Attenuated Vaccine for Human Rabies Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Attenuated Vaccine for Human Rabies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Attenuated Vaccine for Human Rabies Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Attenuated Vaccine for Human Rabies Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Application (2023-2028)
Table 92. AstraZeneca Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 93. AstraZeneca Attenuated Vaccine for Human Rabies Product Offered
Table 94. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. AstraZeneca Main Business
Table 96. AstraZeneca Latest Developments
Table 97. GlaxoSmithKline Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 98. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Offered
Table 99. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. GlaxoSmithKline Main Business
Table 101. GlaxoSmithKline Latest Developments
Table 102. Merck & Co Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 103. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Offered
Table 104. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Merck & Co Inc Main Business
Table 106. Merck & Co Inc Latest Developments
Table 107. Sanofi Pasteur, Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 108. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Offered
Table 109. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Sanofi Pasteur, Inc Main Business
Table 111. Sanofi Pasteur, Inc Latest Developments
Table 112. Cadila Pharmaceuticals Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 113. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 114. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Cadila Pharmaceuticals Ltd Main Business
Table 116. Cadila Pharmaceuticals Ltd Latest Developments
Table 117. Novartis AG Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 118. Novartis AG Attenuated Vaccine for Human Rabies Product Offered
Table 119. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Novartis AG Main Business
Table 121. Novartis AG Latest Developments
Table 122. Pfizer Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 123. Pfizer Inc Attenuated Vaccine for Human Rabies Product Offered
Table 124. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Pfizer Inc Main Business
Table 126. Pfizer Inc Latest Developments
Table 127. Liaoning Yisheng Biopharmaceutical Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 128. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 129. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Liaoning Yisheng Biopharmaceutical Co., Ltd Main Business
Table 131. Liaoning Yisheng Biopharmaceutical Co., Ltd Latest Developments
Table 132. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 133. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 134. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Lanzhou Institute of Biological Products Co., Ltd Main Business
Table 136. Lanzhou Institute of Biological Products Co., Ltd Latest Developments
Table 137. Changchun Zhuoyi Biological Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 138. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 139. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Changchun Zhuoyi Biological Co., Ltd Main Business
Table 141. Changchun Zhuoyi Biological Co., Ltd Latest Developments
Table 142. Guangzhou Nuocheng Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 143. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 144. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Guangzhou Nuocheng Biological Products Co., Ltd Main Business
Table 146. Guangzhou Nuocheng Biological Products Co., Ltd Latest Developments
Table 147. Ningbo Rongan Biopharmaceutical Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 148. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 149. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. Ningbo Rongan Biopharmaceutical Co., Ltd Main Business
Table 151. Ningbo Rongan Biopharmaceutical Co., Ltd Latest Developments
Table 152. Shandong Yidu Biotechnology Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 153. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 154. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 155. Shandong Yidu Biotechnology Co., Ltd Main Business
Table 156. Shandong Yidu Biotechnology Co., Ltd Latest Developments
Table 157. Chengdu Kanghua Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 158. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 159. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 160. Chengdu Kanghua Biological Products Co., Ltd Main Business
Table 161. Chengdu Kanghua Biological Products Co., Ltd Latest Developments
Table 162. Wuhan Institute of Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 163. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 164. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 165. Wuhan Institute of Biological Products Co., Ltd Main Business
Table 166. Wuhan Institute of Biological Products Co., Ltd Latest Developments
Table 1. Attenuated Vaccine for Human Rabies Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Attenuated Vaccine for Human Rabies Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Vero Cell
Table 4. Major Players of Human Diploid Cell
Table 5. Global Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 6. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 7. Global Attenuated Vaccine for Human Rabies Revenue by Type (2017-2022) & ($ million)
Table 8. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2017-2022)
Table 9. Global Attenuated Vaccine for Human Rabies Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 11. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 12. Global Attenuated Vaccine for Human Rabies Revenue by Application (2017-2022)
Table 13. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2017-2022)
Table 14. Global Attenuated Vaccine for Human Rabies Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Attenuated Vaccine for Human Rabies Sales by Company (2020-2022) & (K Units)
Table 16. Global Attenuated Vaccine for Human Rabies Sales Market Share by Company (2020-2022)
Table 17. Global Attenuated Vaccine for Human Rabies Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company (2020-2022)
Table 19. Global Attenuated Vaccine for Human Rabies Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Attenuated Vaccine for Human Rabies Producing Area Distribution and Sales Area
Table 21. Players Attenuated Vaccine for Human Rabies Products Offered
Table 22. Attenuated Vaccine for Human Rabies Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Attenuated Vaccine for Human Rabies Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Attenuated Vaccine for Human Rabies Sales Market Share Geographic Region (2017-2022)
Table 27. Global Attenuated Vaccine for Human Rabies Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Attenuated Vaccine for Human Rabies Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Attenuated Vaccine for Human Rabies Sales Market Share by Country/Region (2017-2022)
Table 31. Global Attenuated Vaccine for Human Rabies Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 34. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 35. Americas Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 37. Americas Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 38. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 39. Americas Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 40. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 41. APAC Attenuated Vaccine for Human Rabies Sales by Region (2017-2022) & (K Units)
Table 42. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)
Table 43. APAC Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2017-2022)
Table 45. APAC Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 46. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 47. APAC Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 48. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 49. Europe Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 50. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 51. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 53. Europe Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 54. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 55. Europe Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 56. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Attenuated Vaccine for Human Rabies Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Attenuated Vaccine for Human Rabies
Table 66. Key Market Challenges & Risks of Attenuated Vaccine for Human Rabies
Table 67. Key Industry Trends of Attenuated Vaccine for Human Rabies
Table 68. Attenuated Vaccine for Human Rabies Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Attenuated Vaccine for Human Rabies Distributors List
Table 71. Attenuated Vaccine for Human Rabies Customer List
Table 72. Global Attenuated Vaccine for Human Rabies Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Attenuated Vaccine for Human Rabies Sales Market Forecast by Region
Table 74. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Attenuated Vaccine for Human Rabies Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Attenuated Vaccine for Human Rabies Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Attenuated Vaccine for Human Rabies Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Attenuated Vaccine for Human Rabies Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Application (2023-2028)
Table 92. AstraZeneca Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 93. AstraZeneca Attenuated Vaccine for Human Rabies Product Offered
Table 94. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. AstraZeneca Main Business
Table 96. AstraZeneca Latest Developments
Table 97. GlaxoSmithKline Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 98. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Offered
Table 99. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. GlaxoSmithKline Main Business
Table 101. GlaxoSmithKline Latest Developments
Table 102. Merck & Co Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 103. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Offered
Table 104. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Merck & Co Inc Main Business
Table 106. Merck & Co Inc Latest Developments
Table 107. Sanofi Pasteur, Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 108. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Offered
Table 109. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Sanofi Pasteur, Inc Main Business
Table 111. Sanofi Pasteur, Inc Latest Developments
Table 112. Cadila Pharmaceuticals Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 113. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 114. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Cadila Pharmaceuticals Ltd Main Business
Table 116. Cadila Pharmaceuticals Ltd Latest Developments
Table 117. Novartis AG Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 118. Novartis AG Attenuated Vaccine for Human Rabies Product Offered
Table 119. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Novartis AG Main Business
Table 121. Novartis AG Latest Developments
Table 122. Pfizer Inc Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 123. Pfizer Inc Attenuated Vaccine for Human Rabies Product Offered
Table 124. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Pfizer Inc Main Business
Table 126. Pfizer Inc Latest Developments
Table 127. Liaoning Yisheng Biopharmaceutical Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 128. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 129. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Liaoning Yisheng Biopharmaceutical Co., Ltd Main Business
Table 131. Liaoning Yisheng Biopharmaceutical Co., Ltd Latest Developments
Table 132. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 133. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 134. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Lanzhou Institute of Biological Products Co., Ltd Main Business
Table 136. Lanzhou Institute of Biological Products Co., Ltd Latest Developments
Table 137. Changchun Zhuoyi Biological Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 138. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 139. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Changchun Zhuoyi Biological Co., Ltd Main Business
Table 141. Changchun Zhuoyi Biological Co., Ltd Latest Developments
Table 142. Guangzhou Nuocheng Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 143. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 144. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Guangzhou Nuocheng Biological Products Co., Ltd Main Business
Table 146. Guangzhou Nuocheng Biological Products Co., Ltd Latest Developments
Table 147. Ningbo Rongan Biopharmaceutical Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 148. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 149. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. Ningbo Rongan Biopharmaceutical Co., Ltd Main Business
Table 151. Ningbo Rongan Biopharmaceutical Co., Ltd Latest Developments
Table 152. Shandong Yidu Biotechnology Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 153. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 154. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 155. Shandong Yidu Biotechnology Co., Ltd Main Business
Table 156. Shandong Yidu Biotechnology Co., Ltd Latest Developments
Table 157. Chengdu Kanghua Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 158. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 159. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 160. Chengdu Kanghua Biological Products Co., Ltd Main Business
Table 161. Chengdu Kanghua Biological Products Co., Ltd Latest Developments
Table 162. Wuhan Institute of Biological Products Co., Ltd Basic Information, Attenuated Vaccine for Human Rabies Manufacturing Base, Sales Area and Its Competitors
Table 163. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Offered
Table 164. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 165. Wuhan Institute of Biological Products Co., Ltd Main Business
Table 166. Wuhan Institute of Biological Products Co., Ltd Latest Developments
LIST OF FIGURES
Figure 1. Picture of Attenuated Vaccine for Human Rabies
Figure 2. Attenuated Vaccine for Human Rabies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Attenuated Vaccine for Human Rabies Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Attenuated Vaccine for Human Rabies Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Attenuated Vaccine for Human Rabies Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Vero Cell
Figure 10. Product Picture of Human Diploid Cell
Figure 11. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type in 2021
Figure 12. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2017-2022)
Figure 13. Attenuated Vaccine for Human Rabies Consumed in Hospital
Figure 14. Global Attenuated Vaccine for Human Rabies Market: Hospital (2017-2022) & (K Units)
Figure 15. Attenuated Vaccine for Human Rabies Consumed in Clinic
Figure 16. Global Attenuated Vaccine for Human Rabies Market: Clinic (2017-2022) & (K Units)
Figure 17. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Figure 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application in 2021
Figure 19. Attenuated Vaccine for Human Rabies Revenue Market by Company in 2021 ($ Million)
Figure 20. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company in 2021
Figure 21. Global Attenuated Vaccine for Human Rabies Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Geographic Region in 2021
Figure 23. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)
Figure 24. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Country/Region in 2021
Figure 25. Americas Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 26. Americas Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 27. APAC Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 28. APAC Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 29. Europe Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 30. Europe Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 32. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 33. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021
Figure 34. Americas Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021
Figure 35. United States Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Region in 2021
Figure 40. APAC Attenuated Vaccine for Human Rabies Revenue Market Share by Regions in 2021
Figure 41. China Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 45. India Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021
Figure 48. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021
Figure 49. Germany Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 50. France Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021
Figure 55. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021
Figure 56. Egypt Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of Attenuated Vaccine for Human Rabies in 2021
Figure 62. Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies
Figure 63. Industry Chain Structure of Attenuated Vaccine for Human Rabies
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Figure 1. Picture of Attenuated Vaccine for Human Rabies
Figure 2. Attenuated Vaccine for Human Rabies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Attenuated Vaccine for Human Rabies Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Attenuated Vaccine for Human Rabies Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Attenuated Vaccine for Human Rabies Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Vero Cell
Figure 10. Product Picture of Human Diploid Cell
Figure 11. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type in 2021
Figure 12. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2017-2022)
Figure 13. Attenuated Vaccine for Human Rabies Consumed in Hospital
Figure 14. Global Attenuated Vaccine for Human Rabies Market: Hospital (2017-2022) & (K Units)
Figure 15. Attenuated Vaccine for Human Rabies Consumed in Clinic
Figure 16. Global Attenuated Vaccine for Human Rabies Market: Clinic (2017-2022) & (K Units)
Figure 17. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Figure 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application in 2021
Figure 19. Attenuated Vaccine for Human Rabies Revenue Market by Company in 2021 ($ Million)
Figure 20. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company in 2021
Figure 21. Global Attenuated Vaccine for Human Rabies Sales Market Share by Geographic Region (2017-2022)
Figure 22. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Geographic Region in 2021
Figure 23. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)
Figure 24. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Country/Region in 2021
Figure 25. Americas Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 26. Americas Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 27. APAC Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 28. APAC Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 29. Europe Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 30. Europe Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 31. Middle East & Africa Attenuated Vaccine for Human Rabies Sales 2017-2022 (K Units)
Figure 32. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue 2017-2022 ($ Millions)
Figure 33. Americas Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021
Figure 34. Americas Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021
Figure 35. United States Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 36. Canada Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 37. Mexico Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 38. Brazil Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 39. APAC Attenuated Vaccine for Human Rabies Sales Market Share by Region in 2021
Figure 40. APAC Attenuated Vaccine for Human Rabies Revenue Market Share by Regions in 2021
Figure 41. China Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 42. Japan Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 43. South Korea Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 44. Southeast Asia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 45. India Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 46. Australia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 47. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021
Figure 48. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021
Figure 49. Germany Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 50. France Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 51. UK Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 52. Italy Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 53. Russia Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 54. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country in 2021
Figure 55. Middle East & Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country in 2021
Figure 56. Egypt Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 57. South Africa Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 58. Israel Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 59. Turkey Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 60. GCC Country Attenuated Vaccine for Human Rabies Revenue Growth 2017-2022 ($ Millions)
Figure 61. Manufacturing Cost Structure Analysis of Attenuated Vaccine for Human Rabies in 2021
Figure 62. Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies
Figure 63. Industry Chain Structure of Attenuated Vaccine for Human Rabies
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
